PTGX compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

PTGXProtagonist Therapeutics, Inc

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

PTGXProtagonist Therapeutics, Inc

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PTGX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.8%▲+6.45%×0.55

May 6 '26±5.3%▲+4.80%×0.91

Q1 FY26±9.0%▲+1.48%×0.17

Q3 FY25±8.9%▼−0.30%×0.03

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedPTGX realized, solidLLY realized, hatchedOne scale, both sides: full bar = 12%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

PTGXProtagonist Therapeutics, Inc

144.19▼−0.11%· post 144.17

Mkt cap$9.4BRevenue$213MQ2 FY26Revenue$46MFY25

LLYELI Lilly & Co

1,412.87▲+2.85%· post 1,417.05

ClosedOct 30 '26

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedOct 30 '26

PTGXProtagonist Therapeutics, Inc

LLYELI Lilly & Co

144.19▼−0.11%post 144.17

Price

1,412.87▲+2.85%post 1,417.05

$9.4B

Mkt cap

$1.3T

Q2 FY26$213M

Revenue

$24.4BQ3 FY26

FY25$46M

Revenue

$65.2BFY25

PTGX144.19▼−0.11%vsLLY1,412.87▲+2.85%ClosedOct 30 '26